Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL
Data At ASH Show Strong Efficacy, Favorable Safety For Umbralisib, Parsaclisib
Neither TG's UNITY-NHL nor Incyte's CITADEL-203 study reported any fatal adverse events - a problem for which Gilead and Verastem's PI3K inhibitors carry boxed warnings.
You may also be interested in...
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
Keeping Track: Parsaclisib, Kymriah Applications Target Non-Hodgkin Lymphomas; AbbVie Gets New Use For Old Ophthalmic
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.